https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6672&f=G&l=50&d=PTXT&p=134&S1=20210824&OS=20210824&RS=20210824
Oppenheimer Maintains Outperform on Iovance Biotherapeutics, Lowers Price Target to $27
Oppenheimer analyst Mark Breidenbach maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Outperform and lowers the price target from $31 to $27.